Navigation Links
MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
Date:11/13/2013

WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second U.S. patent application concerning methods and formulations to achieve targeted tumor cell death.  MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.  MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma.

This invention addresses the need to direct the powerful biological effect of miRNAs such as MCT-485 towards tumor cells and away from normal tissues.  This patent application describes compositions and methods that target populations of cancerous cells which have an enhanced capability to mediate the process of relapse, progression and metastasis.  Not all cancer cells have a tumor initiating capability; this U.S. patent application describes compositions and methods that target cancer by delivering a biologically active, cytotoxic payload of miRNA to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells, and to kill those cells without killing cells not directly involved in the process of relapse, progression and metastasis of cancer.

Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death worldwide.  Over 1 million cases of hepatocellular carcinoma are reported annually.  Current approaches for treatment of hepatocellular carcinoma are of limited efficacy.  MCT-485, possessing both oncolytic and immune activating properties, could be superior to doxorubicin, cisplatin and other currently marketed therapies by providing a more robust activation of immunity, and a more global and longer lasting anti-tumor effect.

About MCT-485

MultiCell Technologies' MCT-485 is a noncoding double stranded micro RNA (miRNA), and the first of a family of prospective cancer therapeutics.  MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485 and other miRNAs.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2012, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer
2. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
3. Life Technologies Announces Third Quarter 2013 Results
4. Bend Research to Highlight Latest Drug Formulation Technologies
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2013 Financial Results on Tuesday, November 12, 2013
6. BioStorage Technologies Selected to Provide Technical Consulting to Chinese National Genebank
7. Adaptive Biotechnologies Publishes Gold Standard Method for Sequencing Cells of the Adaptive Immune System
8. BCC Research Publishes a New Report On Global Markets for Rnai Technologies
9. Forensic Technologies and Services - 2013 Global Strategic Business Report
10. Modality Solutions Releases New White Paper on Thermal Shipping Technologies
11. NPI Volunteers Carry ‘Essential Technologies’ Message to Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... analysis platform specifically designed for life science researchers to analyze and interpret ... Rosalind Franklin, who made a major contribution to the discovery of the ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):